|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: UBA7 |
Gene summary for UBA7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | UBA7 | Gene ID | 7318 |
| Gene name | ubiquitin like modifier activating enzyme 7 | |
| Gene Alias | D8 | |
| Cytomap | 3p21.31 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | P41226 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7318 | UBA7 | C04 | Human | Oral cavity | OSCC | 2.47e-04 | 2.13e-01 | 0.2633 |
| 7318 | UBA7 | C21 | Human | Oral cavity | OSCC | 1.37e-04 | 2.18e-01 | 0.2678 |
| 7318 | UBA7 | C30 | Human | Oral cavity | OSCC | 1.79e-19 | 6.87e-01 | 0.3055 |
| 7318 | UBA7 | C38 | Human | Oral cavity | OSCC | 2.45e-03 | 4.61e-01 | 0.172 |
| 7318 | UBA7 | C46 | Human | Oral cavity | OSCC | 2.87e-28 | 6.24e-01 | 0.1673 |
| 7318 | UBA7 | C51 | Human | Oral cavity | OSCC | 2.29e-03 | 2.68e-01 | 0.2674 |
| 7318 | UBA7 | LN22 | Human | Oral cavity | OSCC | 1.25e-06 | 6.62e-01 | 0.1733 |
| 7318 | UBA7 | LN46 | Human | Oral cavity | OSCC | 4.92e-12 | 4.51e-01 | 0.1666 |
| 7318 | UBA7 | LP15 | Human | Oral cavity | LP | 7.40e-05 | 6.99e-01 | 0.2174 |
| 7318 | UBA7 | SYSMH2 | Human | Oral cavity | OSCC | 1.04e-03 | 2.07e-01 | 0.2326 |
| 7318 | UBA7 | SYSMH3 | Human | Oral cavity | OSCC | 4.46e-04 | 1.85e-01 | 0.2442 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0501230 | Oral cavity | OSCC | Parkinson disease | 188/3704 | 266/8465 | 1.82e-19 | 1.52e-17 | 7.75e-18 | 188 |
| hsa0502228 | Oral cavity | OSCC | Pathways of neurodegeneration - multiple diseases | 292/3704 | 476/8465 | 1.60e-15 | 4.47e-14 | 2.28e-14 | 292 |
| hsa0412020 | Oral cavity | OSCC | Ubiquitin mediated proteolysis | 105/3704 | 142/8465 | 1.83e-13 | 4.37e-12 | 2.23e-12 | 105 |
| hsa05012113 | Oral cavity | OSCC | Parkinson disease | 188/3704 | 266/8465 | 1.82e-19 | 1.52e-17 | 7.75e-18 | 188 |
| hsa05022112 | Oral cavity | OSCC | Pathways of neurodegeneration - multiple diseases | 292/3704 | 476/8465 | 1.60e-15 | 4.47e-14 | 2.28e-14 | 292 |
| hsa04120110 | Oral cavity | OSCC | Ubiquitin mediated proteolysis | 105/3704 | 142/8465 | 1.83e-13 | 4.37e-12 | 2.23e-12 | 105 |
| hsa05012210 | Oral cavity | LP | Parkinson disease | 166/2418 | 266/8465 | 2.02e-31 | 3.36e-29 | 2.17e-29 | 166 |
| hsa0502229 | Oral cavity | LP | Pathways of neurodegeneration - multiple diseases | 232/2418 | 476/8465 | 7.77e-22 | 3.69e-20 | 2.38e-20 | 232 |
| hsa0412025 | Oral cavity | LP | Ubiquitin mediated proteolysis | 66/2418 | 142/8465 | 3.74e-06 | 3.46e-05 | 2.23e-05 | 66 |
| hsa0501238 | Oral cavity | LP | Parkinson disease | 166/2418 | 266/8465 | 2.02e-31 | 3.36e-29 | 2.17e-29 | 166 |
| hsa0502237 | Oral cavity | LP | Pathways of neurodegeneration - multiple diseases | 232/2418 | 476/8465 | 7.77e-22 | 3.69e-20 | 2.38e-20 | 232 |
| hsa0412035 | Oral cavity | LP | Ubiquitin mediated proteolysis | 66/2418 | 142/8465 | 3.74e-06 | 3.46e-05 | 2.23e-05 | 66 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| UBA7 | SNV | Missense_Mutation | novel | c.1699N>C | p.Thr567Pro | p.T567P | P41226 | protein_coding | deleterious(0) | possibly_damaging(0.708) | TCGA-AO-A03V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
| UBA7 | SNV | Missense_Mutation | c.1760N>T | p.Ser587Leu | p.S587L | P41226 | protein_coding | deleterious(0) | benign(0.014) | TCGA-B6-A0IB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| UBA7 | SNV | Missense_Mutation | c.2445N>A | p.Asn815Lys | p.N815K | P41226 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| UBA7 | SNV | Missense_Mutation | c.163N>T | p.Gly55Cys | p.G55C | P41226 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| UBA7 | SNV | Missense_Mutation | rs545334951 | c.2645G>A | p.Arg882His | p.R882H | P41226 | protein_coding | deleterious(0) | possibly_damaging(0.763) | TCGA-E2-A1LK-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| UBA7 | deletion | Frame_Shift_Del | novel | c.375delN | p.Ala126LeufsTer8 | p.A126Lfs*8 | P41226 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| UBA7 | SNV | Missense_Mutation | novel | c.428G>A | p.Gly143Glu | p.G143E | P41226 | protein_coding | deleterious(0) | possibly_damaging(0.521) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| UBA7 | SNV | Missense_Mutation | rs150856419 | c.2998N>A | p.Asp1000Asn | p.D1000N | P41226 | protein_coding | tolerated(0.08) | benign(0.013) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| UBA7 | SNV | Missense_Mutation | rs776826132 | c.2330N>T | p.Ser777Leu | p.S777L | P41226 | protein_coding | tolerated(0.27) | benign(0.022) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| UBA7 | SNV | Missense_Mutation | c.809N>T | p.Ala270Val | p.A270V | P41226 | protein_coding | deleterious(0) | benign(0.08) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |